Guidance supports framework for accelerating development of individualized therapies The U.S. Food and Drug Administration today issued a draft guidance for sponsors seeking approval of human gene therapy products involving genome editing technologies.
When finalized, this guidance will provide recommendations for standardized methods for comprehensively assessing the safety of genome editing therapies to bring effective treatments to patients sooner. “Genome editing holds extraordinary promise for treating previously incurable genetic diseases, and today’s announcement represents the FDA's forward approach to drive innovation and advance the development of genome editing therapies,” said FDA Commissioner Marty Makary, M.D., M.P.H.
“This guidance provides sponsors with clear, scientifically-grounded recommendations for evaluating off-target editing risks using state-of-the-art sequencing technologies. We are serious about moving this ball forward.” The draft guidance, issued by the Center for Biologics Evaluation and Research, supports the FDA’s framework for accelerating development of individualized therapies for ultra-rare diseases launched in February.
The framework revolutionizes how the FDA engages with industry and promotes a path for transformative rare disease treatments.
The stated purpose of the guidance is to standardize methods for comprehensively evaluating safety, with the ultimate goal of expediting access to effective, individualized therapies for patients.
The initiative aligns with the FDA’s broader framework to accelerate development of treatments for ultra-rare diseases and to foster collaboration with industry in pursuit of transformative, targeted interventions.
The focus is on evaluating potential safety risks such as off-target editing events and loss of genome integrity.
They apply to both ex vivo products (where cells are edited outside the body) and in vivo products (where editing occurs within patient tissues).
The emphasis is on balancing thorough safety characterization with facilitating timely advancement toward clinical testing.
Mechanisms highlighted for dialogue include INTERACT (Initial Targeted Engagement for Regulatory Advice on CBER/CDER Products) and pre-IND meetings, where sponsors can discuss development strategies relevant to genome editing therapies.
Submitted comments will be reviewed prior to finalization of the guidance.
It does not, within the provided text, convey quantitative data, study outcomes, or explicit performance benchmarks.
regulatory framework.
Any practical implications for trial design or manufacturing practices will depend on the final language of the guidance.